Athersys, Inc. , a regenerative medicine company developing MultiStem® cell therapy for critical care indications, announced today its participation in three upcoming conferences during the. | May 8, 2023
CLEVELAND (BUSINESS WIRE) Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced today its participation in three upcoming conferences during the month of May. Chris Temple, Vice President of Operations, will be par.